|
注册号: Registration number: |
ChiCTR2200056780 |
|
最近更新日期: Date of Last Refreshed on: |
2022-02-16 09:17:03 |
|
注册时间: Date of Registration: |
2022-02-16 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
针对原发性骨质疏松症的个性化运动处方设计与应用研究 |
|
Public title: |
Design and application of personalized exercise prescription for primary osteoporosis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
针对原发性骨质疏松症的个性化运动处方设计与应用研究 |
|
Scientific title: |
Design and application of personalized exercise prescription for primary osteoporosis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张达宽 |
研究负责人: |
李永杰 |
|
Applicant: |
Zhangdakuan |
Study leader: |
Liyongjie |
|
申请注册联系人电话: Applicant telephone: |
18885809889 |
研究负责人电话:
Study leader's |
18530177199 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
781657643@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
750199003@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
贵阳市白云区思贤街206号 |
研究负责人通讯地址: |
贵阳市白云区思贤街206号 |
|
Applicant address: |
No. 206, Sixian Street, Baiyun District, Guiyang City |
Study leader's address: |
No. 206, Sixian Street, Baiyun District, Guiyang City |
|
申请注册联系人邮政编码: Applicant postcode: |
550002 |
研究负责人邮政编码: Study leader's postcode: |
550002 |
|
申请人所在单位: |
贵州省骨科医院 |
||
|
Applicant's institution: |
Guizhou orthopedic hospital |
||
|
研究负责人所在单位: |
贵州省骨科医院 |
||
|
Affiliation of the Leader: |
Guizhou orthopedic hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
LW2021101401 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
贵州省骨科医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Guizhou Orthopaedic Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-10-14 00:00:00 | ||
|
伦理委员会联系人: |
廖永芳 |
||
|
Contact Name of the ethic committee: |
LiaoYongfang |
||
|
伦理委员会联系地址: |
贵阳市白云区思贤街206号 |
||
|
Contact Address of the ethic committee: |
No. 206, Sixian Street, Baiyun District, Guiyang City |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
贵州省骨科医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Guizhou orthopedic hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
贵州省骨科医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Guizhou orthopedic hospital |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
贵州省骨科医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
Guizhou orthopedic hospital |
||||||||||||||||||||||
|
研究疾病: |
原发性骨质疏松症 |
||||||||||||||||||||||
|
Target disease: |
primary osteoporosis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究拟建立以易筋经为基础,并联合跑台运动和力量训练的个性化运动处方,进而观察其对POP患者疼痛、肌力、平衡、骨密度和骨代谢指标的影响。本研究旨在丰富POP患者运动康复处方的内容和形式,提高该人群的运动康复效果,改善生活质量,为更加科学、精准地服务于健康中国建设提供有力保障。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study intends to establish a personalized exercise prescription based on Yijinjing combined with treadmill exercise and strength training, and then observe its effects on pain, muscle strength, balance, bone mineral density and bone metabolism in patients with pop. The purpose of this study is to enrich the content and form of exercise rehabilitation prescriptions for pop patients, improve the effect of exercise rehabilitation, improve the quality of life, and provide a strong guarantee for more scientific and accurate service to the construction of healthy China. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
①继发性骨质疏松症及其他原因引起的骨质疏松症 |
||||||||||||||||||||||
|
Exclusion criteria: |
① Secondary osteoporosis and osteoporosis caused by other reasons |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-01-01 00:00:00至 To 2023-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-02-16 00:00:00 至 To 2023-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
在研究对象充分知情同意的前提下,由统计人员在研究开始前用计算机产生随机分配序列;随机分配序列被放入按顺序编码、密封、不透光的信封中;当临床研究人员确定受试对象合格后,按顺序拆开信封,将受试对象分配入相应的组别。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
On the premise of the full informed consent of the research object, the statisticians use the computer to generate the random distribution sequence before the beginning of the research; The randomly assigned sequence is put into sequentially coded, sealed and opaque envelopes; When the clinical researcher determine |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
本研究不考虑原始数据共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
This study does not consider raw data sharing |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统(EDC,ResMan) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture (EDC, ResMan) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |